The purpose of this study is to test a potential new treatment for ovarian, peritoneal or fallopian tube cancer called ZN-c3-also known as azenosertib.
This study that will investigate the study drug ZN-c3 to find out if it is safe and whether it will slow or stop the spread of your cancer when taken in combination with chemotherapy such as PLD (pegylated liposomal doxorubicin), Paclitaxel, carboplatin, or gemcitabine.
- Category
-
Trial status
Recruiting
-
Trial phase
Phase 1 Drug TrialEarly stage studies seeking initial evidence of safety, dosage and efficacy in small numbers of patients or healthy volunteers.
-
ERM Project ID
69078
Trial contact details
-
Contact person
Caitlin Bennett
-
Phone
07 3163 7689
What you need to know
Who can take part?
Patients with ovarian, peritoneal or fallopian tube cancer that has spread and has not responded to treatment with other chemotherapy agents including carboplatin or cisplatin.
What is involved for you?
The trial goes for approximately 30 months during which you will see your doctor and research coordinator 2-3 times per month. During these visits you may have a physical exams, ECG, blood tests, tumour assessments (ie-CT scans) and revieve the chemotherapy that has been prescribed by your doctor. As well, you will be taking the study drug alongside the chemotherapy.
